Carisma Therapeutics (CARM) Competitors $0.27 +0.01 (+2.90%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$0.28 +0.01 (+3.70%) As of 07:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, LTRN, PDSB, AADI, MDCX, NBRV, SCYX, TELO, ESLA, and IPSCShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Aadi Bioscience (AADI), Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Telomir Pharmaceuticals (TELO), Estrella Immunopharma (ESLA), and Century Therapeutics (IPSC). These companies are all part of the "medical" sector. Carisma Therapeutics vs. Its Competitors Evogene Lantern Pharma PDS Biotechnology Aadi Bioscience Medicus Pharma Nabriva Therapeutics SCYNEXIS Telomir Pharmaceuticals Estrella Immunopharma Century Therapeutics Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation. Does the media favor EVGN or CARM? In the previous week, Carisma Therapeutics had 6 more articles in the media than Evogene. MarketBeat recorded 8 mentions for Carisma Therapeutics and 2 mentions for Evogene. Evogene's average media sentiment score of 0.00 beat Carisma Therapeutics' score of -0.23 indicating that Evogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Carisma Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in EVGN or CARM? 10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is EVGN or CARM more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Evogene-211.61% -109.96% -38.47% Carisma Therapeutics -254.28%N/A -192.17% Do analysts prefer EVGN or CARM? Evogene presently has a consensus target price of $3.50, indicating a potential upside of 139.73%. Carisma Therapeutics has a consensus target price of $1.93, indicating a potential upside of 612.96%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Carisma Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.50 Which has more volatility & risk, EVGN or CARM? Evogene has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Which has better earnings and valuation, EVGN or CARM? Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvogene$9.44M0.83-$16.49M-$2.25-0.65Carisma Therapeutics$19.63M0.57-$60.48M-$1.56-0.17 SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.97M$2.62B$6.09B$10.54BDividend YieldN/A56.71%5.69%4.71%P/E Ratio-0.1723.6985.4827.61Price / Sales0.57571.62535.60201.12Price / CashN/A173.2337.9261.55Price / Book-0.405.5312.976.76Net Income-$60.48M$32.78M$3.30B$275.88M7 Day PerformanceN/A5.82%4.35%2.81%1 Month Performance-34.77%13.16%9.50%9.24%1 Year Performance-71.87%1.69%84.38%35.42% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics2.3198 of 5 stars$0.27+2.9%$1.93+613.0%-69.1%$10.97M$19.63M-0.1720News CoverageAnalyst ForecastEVGNEvogene2.332 of 5 stars$1.18+3.5%$3.50+196.6%-47.3%$6.12M$9.44M-0.52140News CoveragePositive NewsAnalyst ForecastLTRNLantern Pharma2.0199 of 5 stars$4.54+2.0%$25.00+450.7%+24.4%$48.11MN/A-2.5520Analyst ForecastPDSBPDS Biotechnology1.6679 of 5 stars$1.01-1.0%$10.00+890.1%-71.9%$47.97MN/A-1.1020Analyst ForecastAADIAadi BioscienceN/A$1.94+2.6%N/A+13.8%$47.91M$25.07M-0.8540MDCXMedicus Pharma2.6634 of 5 stars$2.51-4.6%$23.50+836.3%N/A$46.86MN/A-1.87N/AAnalyst ForecastNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070SCYXSCYNEXIS0.463 of 5 stars$1.05-2.3%N/A-47.9%$45.07M$3.26M-2.6260Gap UpTELOTelomir Pharmaceuticals2.8025 of 5 stars$1.34-3.6%$15.00+1,019.4%-68.3%$44.87MN/A-2.481Analyst ForecastGap DownESLAEstrella Immunopharma1.9951 of 5 stars$1.19-0.8%$16.00+1,244.5%+40.3%$44.48MN/A-4.58N/ANews CoveragePositive NewsAnalyst ForecastGap UpIPSCCentury Therapeutics2.4576 of 5 stars$0.50-1.9%$3.75+650.6%-60.0%$43.98M$6.59M-1.72170Analyst ForecastGap Up Related Companies and Tools Related Companies Evogene Alternatives Lantern Pharma Alternatives PDS Biotechnology Alternatives Aadi Bioscience Alternatives Medicus Pharma Alternatives Nabriva Therapeutics Alternatives SCYNEXIS Alternatives Telomir Pharmaceuticals Alternatives Estrella Immunopharma Alternatives Century Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
